|
PPARGC1A
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our data demonstrate that sphingolipid balance, and increased AMPK, SIRT1, PGC-1α, and CS protein expression are part of the mechanism that contributes to the remission of diabetes after RYGB surgery.
|
30809769 |
2019 |
|
PPARGC1A
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This review summarizes a growing body of literature surrounding possible links between the PGC-1α Gly482Ser single nucleotide polymorphism and diabetes, with focus on key clinical findings, affected metabolic systems, potential molecular mechanisms, and the influence of geographical or ethnic background on associated risk.
|
29186342 |
2018 |
|
PPARGC1A
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The molecular mechanisms underlying the regulation of PGC-1α in placenta in the context of diabetes remain unclear.
|
28433632 |
2017 |
|
PPARGC1A
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, despite decreased PGC-1α, concomitant changes in TFAM and mtDNA content by diabetes were not observed in females.
|
28864016 |
2017 |
|
PPARGC1A
|
0.100 |
Biomarker
|
disease |
BEFREE |
Yet, it may not represent a useful target for therapeutic strategies against diabetes as it exerts both beneficial and deleterious actions on glucose homoeostasis, and because PGC-1α modulation is involved in neurodegenerative diseases.
|
25753246 |
2015 |
|
PPARGC1A
|
0.100 |
Biomarker
|
disease |
BEFREE |
The mitochondrial protective gene PGC-1α is also closely related to diabetes, and UCP2 is related to anti-mitochondrial oxidative stress, but the mechanism of action of these genes is unclear.
|
26315270 |
2015 |
|
PPARGC1A
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of PGC-1α or control of hyperglycemia may be beneficial in improving the efficacy of chemotherapy in MM patients with diabetes.
|
25695395 |
2015 |
|
PPARGC1A
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, these results provide new insights into potential cooperative roles of PINK1 and PGC-1α in mitochondrial fatty acid oxidation, suggesting possible regulatory roles for mitochondrial function in the pathogenesis of AD and diabetes.
|
25260493 |
2014 |
|
PPARGC1A
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Therefore, we examined the mechanism responsible for decreased PGC-1alpha expression using a rodent streptozotocin (STZ) model of chronic diabetes and atrophy.
|
20359506 |
2010 |
|
PPARGC1A
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Acute exercise caused a fourfold increase in PGC-1alpha expression in muscle from control subjects but not in subjects with diabetes.
|
20032281 |
2010 |
|
PPARGC1A
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We review the evidence for relationships between thyroid hormone action and diabetes risk, and discuss potential mechanisms linking intracellular thyroid hormone availability, thyroid receptor action, and the transcriptional coactivator PGC1 in regulating oxidative metabolism.
|
18279023 |
2008 |
|
PPARGC1A
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The Gly482Ser polymorphism in peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PPARGC1A) has been demonstrated to be associated with diabetes, obesity and hypertension, all of which are important risk factors for left ventricular diastolic dysfunction.
|
19077249 |
2008 |
|
PPARGC1A
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Interestingly, five positional candidate genes for diabetes and related complications are located in our linkage region (the pituitary adenylate cyclase activating polypeptide (PACAP in 18p11); the peroxisome proliferator-activated receptor gamma coactivator 1 (PPARGC1 in 4p15); PTEN, PPP1R5, and IDE located in 10q23.
|
17548123 |
2007 |
|
PPARGC1A
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thus, PGC-1alpha sequence variation may interact with physical activity to modify diabetes risk via changes in oxidative energy metabolism.
|
17031255 |
2006 |
|
PPARGC1A
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent studies have elucidated the function of the PGC-1 coactivators in different tissues and have highlighted the implications of PGC-1 dysregulation in diseases such as diabetes, obesity, cardiomyopathy, or neurodegeneration.
|
17018837 |
2006 |
|
PPARGC1A
|
0.100 |
Biomarker
|
disease |
BEFREE |
This Review focuses on the biologic and physiologic functions of the PGC-1 coactivators, with particular emphasis on striated muscle, liver, and other organ systems relevant to common diseases such as diabetes and heart failure.
|
16511594 |
2006 |
|
PPARGC1A
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In population studies a Gly482Ser substitution in PGC-1alpha has been reported to be associated with increased risk of type diabetes 2 and insulin resistance.
|
16403952 |
2005 |
|
PPARGC1A
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conclude that PPARGC1A is likely to contribute to the risk of diabetes in offspring of patients with type 2 diabetes.
|
15912394 |
2005 |
|
PPARGC1A
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To address this question we studied expression of these genes in muscle biopsies obtained from young and elderly dizygotic and monozygotic twins without known diabetes before and after insulin stimulation and related the expression to a Gly482Ser variant in the PGC-1alpha gene.
|
15546003 |
2004 |
|
PPARGC1A
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes.
|
12808457 |
2003 |
|
PPARGC1A
|
0.100 |
Biomarker
|
disease |
BEFREE |
Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1.
|
12832613 |
2003 |
|
PPARGC1A
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, PGC-1alpha is a key activator of CYP7A1 and bile acid biosynthesis and is likely responsible for the fasting and diabetes dependent induction of CYP7A1.
|
14522988 |
2003 |